Treatment of Chlamydia Pneumonia
First-Line Treatment Options
- The American College of Physicians recommends doxycycline 100 mg orally twice daily for 7-14 days or azithromycin 500 mg orally on day 1, followed by 250 mg daily for 4 days as first-line treatment for Chlamydia pneumonia 1, 2
- Azithromycin 500 mg orally on day 1, followed by 250 mg daily for 4 days is equally effective as doxycycline for treating Chlamydia pneumonia 1
Alternative Treatment Options
- The Infectious Diseases Society of America recommends levofloxacin 500-750 mg orally/IV once daily for 7-10 days as an alternative treatment option for Chlamydia pneumonia 1
- Moxifloxacin 400 mg orally/IV once daily for 10 days is an alternative treatment option for Chlamydia pneumonia 1
- Clarithromycin 500 mg orally twice daily for 10 days is an alternative treatment option for Chlamydia pneumonia 1
- Erythromycin 500 mg orally four times daily for 10-14 days is a less preferred alternative treatment option for Chlamydia pneumonia due to gastrointestinal side effects 1
Treatment Considerations
- The Centers for Disease Control and Prevention notes that doxycycline has a lower cost compared to azithromycin 2
- Doxycycline has extensive clinical experience with high cure rates for Chlamydia pneumonia 2
- Azithromycin has better compliance due to shorter course and fewer daily doses 2
Special Populations
- The American College of Obstetricians and Gynecologists recommends erythromycin base 500 mg orally four times daily for 7 days as the preferred treatment for Chlamydia pneumonia during pregnancy 3, 2
- Amoxicillin 500 mg orally three times daily for 7-10 days is an alternative treatment option for Chlamydia pneumonia during pregnancy if erythromycin cannot be tolerated 3, 4
- For children ≥8 years who weigh >45 kg, the same adult dosing of doxycycline or azithromycin is recommended 4
- For children <8 years, azithromycin is preferred due to risk of dental staining with doxycycline 5
Clinical Pearls and Pitfalls
- Treatment failure is uncommon with recommended regimens, with failure rates of 0-3% for males and 0-8% for females 3